Cargando…

In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia

Thrombocytopenia is common among critically ill sepsis patients, while they also hold an increased risk for thromboembolic events. Thus, the choice of anticoagulant prophylaxis for this patient population is challenging. We investigated the in vitro effect of low-molecular-weight heparin (dalteparin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nygaard, Søren, Hvas, Christine L., Hvas, Anne-Mette, Adelborg, Kasper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886503/ https://www.ncbi.nlm.nih.gov/pubmed/36751302 http://dx.doi.org/10.1055/a-2000-6576

Ejemplares similares

Exploring the epidemiology of disseminated intravascular coagulation: protocol for the DANish Disseminated Intravascular Coagulation (DANDIC) Cohort Study
por: Flæng, Simon, et al.
Publicado: (2022)

Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review
por: Bachler, Mirjam, et al.
Publicado: (2022)

Effect of remote ischemic preconditioning on hemostasis and fibrinolysis in head and neck cancer surgery: A randomized controlled trial
por: Krag, Andreas Engel, et al.
Publicado: (2019)

Argatroban in the management of heparin-induced thrombocytopenia
por: Babuin, Luciano, et al.
Publicado: (2010)

Argatroban for heparin-induced thrombocytopenia therapy in ICU patients with sepsis or multiple organ dysfunction syndrome
por: Saugel, B, et al.
Publicado: (2009)

Disseminated intravascular coagulation diagnosis: Positive predictive value of the ISTH score in a Danish population
por: Larsen, Julie Brogaard, et al.
Publicado: (2021)

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
por: Tardy-Poncet, Brigitte, et al.
Publicado: (2015)

Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II
por: Grouzi, Elisavet
Publicado: (2014)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2020)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2021)

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
por: van der Heijden, Charlotte D. C. C., et al.
Publicado: (2022)

Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial
por: Treschan, Tanja A, et al.
Publicado: (2014)

Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis
por: Kim, Se-Chan, et al.
Publicado: (2015)

Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019
por: Ogawa, Yoshihiko, et al.
Publicado: (2020)

A Case Report and Literature Review on Argatroban Refractory Heparin-Induced Thrombocytopenia
por: Deen, Imad U., et al.
Publicado: (2022)

Efficacy and Safety of Oral Anticoagulants in Patients with Systolic Heart Failure in Sinus Rhythm: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Cohort Studies
por: Nygaard, Marie H., et al.
Publicado: (2020)

Argatroban/azd-1222/dexamethasone: Thrombotic thrombocytopenia and lack of efficacy: 3 case reports
Publicado: (2021)

Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis
por: Colarossi, Giorgia, et al.
Publicado: (2021)

Inter-α-inhibitor heavy chain H4 and sepsis-related coagulation disturbances: Another link between innate immunity and coagulation
por: Larsen, Julie Brogaard, et al.
Publicado: (2023)

AZD-1222/dalteparin-sodium/heparin: Venous thrombosis, thrombocytopenia and lack of efficacy: 5 case reports
Publicado: (2021)

Remote Ischemic Preconditioning in Microsurgical Head and Neck Reconstruction: A Randomized Controlled Trial
por: Krag, Andreas E., et al.
Publicado: (2020)

A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra(®)) in Critically Ill Patients with Heparin Resistance †
por: Bachler, Mirjam, et al.
Publicado: (2020)

Successful Use of Argatroban to Treat a Critically Ill Patient with Coagulopathy and Nephropathy Secondary to COVID-19
por: Frise, Matthew C., et al.
Publicado: (2020)

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban
por: Guetl, Katharina, et al.
Publicado: (2021)

Histone-DNA Complexes and Coagulation after Intracerebral and Subarachnoid Hemorrhage
por: Gyldenholm, Tua, et al.
Publicado: (2021)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Managing argatroban in heparin‐induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin‐induced thrombocytopenia
por: Marchetti, Matteo, et al.
Publicado: (2022)

Use of argatroban for extracorporeal life support in patients with nonheparin-induced thrombocytopenia: Analysis of 10 consecutive patients
por: Kim, Young Su, et al.
Publicado: (2018)

Anticoagulation with Argatroban in a Patient with Heparin-Induced Thrombocytopenia and Renal Insufficiency Undergoing Orthotopic Heart Transplantation
por: Green, Michael Stuart, et al.
Publicado: (2021)

Fibrin Network Formation and Lysis in Septic Shock Patients
por: Larsen, Julie Brogaard, et al.
Publicado: (2021)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

Neonatal Sepsis and Hemostasis
por: Gialamprinou, Dimitra, et al.
Publicado: (2022)

Does dalteparin PROTECT better than heparin?
por: Przybysz, Thomas, et al.
Publicado: (2011)

Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis
por: Ostrowski, Sisse R., et al.
Publicado: (2021)

Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study
por: Saugel, Bernd, et al.
Publicado: (2010)

Successful Management of Heparin-Induced Thrombocytopenia Using Argatroban in a Very Old Woman: A Case Report
por: Putot, A., et al.
Publicado: (2013)

Argatroban caused severe hypercholesterolaemia in a chronic haemodialysis patient with heparin-induced thrombocytopenia: an unreported adverse effect?
por: Nakagawa, Tetsuya
Publicado: (2008)

Bleeding patients on extracorporeal membrane oxygenation have reduced platelet aggregation and plasma fibrinogen: a longitudinal observational study
por: Hvas, Christine Lodberg, et al.
Publicado: (2023)

Correction: Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study
por: Saugel, Bernd, et al.
Publicado: (2012)

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_i6qcrqdb6f652o74nj5b7b5vfc